AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,166.00p
   
  • Change Today:
    -6.00p
  • 52 Week High: 12,370.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.24m
  • Volume: 1,607,422
  • Market Cap: £188,602m
  • RiskGrade: 123

Director dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m

By Josh White

Date: Tuesday 02 May 2023

LONDON (ShareCast) - (Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.
Under the shareholder-approved remuneration policy, Kokke would receive a basic annual salary of $825,000, along with a pension contribution worth 6% of his salary.

Additionally, he would receive payments of £4m, mostly in Genus share awards, as compensation for incentives he held at his previous company, Ingredion.

He would also be eligible for an annual bonus of up to 200% of his salary, with one-third of any bonus paid deferred into shares, and a long-term incentive award of 400% of his salary in September, subject to performance targets and a two-year holding period.

At 1301 BST, shares in Genus were down 0.22% at 2,682p.

K3 Business Technology Group, meanwhile, was in the red after Kestrel Partners acquired 76,564 ordinary shares at an average price of £1.10 per share on 21 April.

Kestrel is indirectly holding voting rights over 26.4% of the company's issued share capital.

On 28 April, Kestrel acquired an additional 2,027 shares at an average price of £1.10 apiece, increasing its indirect voting rights to 26.41% of the company's issued share capital.

K3 said non-executive director Oliver Scott is a partner of Kestrel, and holds a beneficial interest in one of Kestrel's clients, which was deemed to have a beneficial interest in Kestrel's entire legal holding in the company.

At 1052 BST, shares in K3 Business Technology Group were down 2.22% at 110p.

Pharmaceuticals giant AstraZeneca was also in focus after its non-executive chair Michel Demaré purchased 2,000 of its ordinary shares on 28 April, at a price of £117.01 per share, for a total value of £234,020.

At 1307 BST, shares in AstraZeneca were down 0.14% at 11,730p.

Finally, ix Net Zero, an investing company focusing on energy transition and sustainability in the built environment, saw its shares slide despite one of its non-executive directors, Patricia McCall, buying 20,000 shares on 28 April.

McCall paid 13p per share, for a total value of £2,600.

Following this purchase, McCall owned 63,139 ordinary shares, representing 0.1% of the company's shares in issue.

At 1231 BST, shares in ix Net Zero were down 10.42% at 16.12p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,166.00p
Change Today -6.00p
% Change -0.05 %
52 Week High 12,370.00p
52 Week Low 9,501.00p
Volume 1,607,422
Shares Issued 1,550.24m
Market Cap £188,602m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.21% below the market average92.21% below the market average92.21% below the market average92.21% below the market average92.21% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
56.28% above the market average56.28% above the market average56.28% above the market average56.28% above the market average56.28% above the market average
74.07% above the sector average74.07% above the sector average74.07% above the sector average74.07% above the sector average74.07% above the sector average
Income
91.18% below the market average91.18% below the market average91.18% below the market average91.18% below the market average91.18% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.58% above the market average82.58% above the market average82.58% above the market average82.58% above the market average82.58% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 8
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 16-May-2024

Time Volume / Share Price
16:19 0 @ 12,108.00p
16:19 0 @ 12,108.00p
16:16 0 @ 12,102.00p
16:16 0 @ 12,098.00p
16:14 0 @ 12,104.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page